EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recent Advances in Screening for Barrett’s Esophagus

Sarmed S Sami, Prasad G Iyer

Current Treatment Options in Gastroenterology · 2018-03 · 16 (1) · 1-14

DOI: 10.1007/s11938-018-0166-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Gastroenterology, online erschienen am 13.01.2018. Verfasst von Sarmed S Sami und 1 weiteren Autor:innen. Beteiligte Einrichtung: Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: PURPOSE OF REVIEW: There is a pressing need for effective strategies to halt the increase in both the incidence and mortality of esophageal adenocarcinoma (EAC). Screening for Barrett's esophagus, which is the only known precursor of EAC, remains a ripe area for research, particularly with regard to identifying the target population, screening tools, and management of screen-detected populations. This review aims to explore in depth the rationale for screening for Barrett's esophagus, recent biotechnological advances which may have the potential of making screening feasible, and also highlight the challenges which will have to be overcome in order make screening for BE a realistic prospect. RECENT FINDINGS: Imaging techniques such as portable transnasal endoscopy have the advantage of providing an immediate diagnosis of Barrett's esophagus as well as other significant pathologies such as reflux esophagitis and cancer; however, larger studies in non-enriched community screening populations are required to evaluate their feasibility. The capsule sponge is a cell-sampling device coupled with a biomarker, which has been most extensively evaluated with very promising results as regards feasibility, acceptability, accuracy, and cost-effectiveness. Its effectiveness in increasing the detection of Barrett's esophagus in primary care is currently being evaluated. Several Barrett's esophagus risk prediction scores have been developed with variable degrees of accuracy. Several minimally and non-invasive screening techniques have been studied including imaging and cell-sampling devices. Barrett's risk assessment models need to be further validated in independent, relevant screening populations with clear cut-offs for recommending screening to be defined.

Schlagwörter

Stichwörter der Autor:innen

Barrett’s esophagusEsophageal adenocarcinomaRisk stratificationScreeningScreening tools

Autor:innen und Institutionen

  • Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
  • Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. iyer.prasad@mayo.edu.

Förderung

  • NCI NIH HHS

Zitieren

APA

Sami, S. S., & Iyer, P. G. (2018). Recent Advances in Screening for Barrett’s Esophagus. Current Treatment Options in Gastroenterology, 16(1), 1-14. https://doi.org/10.1007/s11938-018-0166-2

Vancouver

Sami SS, Iyer PG. Recent Advances in Screening for Barrett’s Esophagus. Current Treatment Options in Gastroenterology. 2018;16(1):1-14. doi:10.1007/s11938-018-0166-2

BibTeX
@article{Sami2018,
  author = {Sami, Sarmed S and Iyer, Prasad G},
  title = {Recent Advances in Screening for Barrett’s Esophagus},
  journal = {Current Treatment Options in Gastroenterology},
  year = {2018},
  volume = {16},
  number = {1},
  pages = {1--14},
  doi = {10.1007/s11938-018-0166-2}
}
Kostenlos starten →